Davis Polk advised the representatives of the several underwriters in connection with the $115 million public offering of 19,166,667 common shares of Affimed N.V. The offering included 2,500,000 common shares sold by Affimed pursuant to the underwriters’ exercise in full of their over-allotment option. The common shares are listed on the Nasdaq Global Market under the symbol “AFMD.”
Based in Heidelberg, Germany, Affimed is a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors.
The Davis Polk corporate team included partner Derek Dostal and associates Dan Gibbons, Johnathan M. Nixon and Xi (Brooke) Zheng. The tax team included partner Patrick E. Sigmon. The intellectual property and technology transactions team included partner David R. Bauer and associate Jesse L. Hallock. All members of the Davis Polk team are based in the New York office.